The Antibody Society’s symposium at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS) was held June 20, 2018, in San Francisco, CA. Presentations from the Symposium can be found on the Presentations page in the Members Only section of the Society’s website. Please login to access the PDFs, posted when speakers have provided permission.
The topic was “Antibodies in the prevention and treatment of human disease”. Antibodies carry an enormous potential in prophylaxis and treatment of human disease, for all ages, both genders, and all races, irrespective of geographic location. Antibody therapies are leveraged in two distinct, but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response and the science of eliciting such antibodies in vivo is progressing rapidly. We may now take advantage of incredibly detailed repertoire analysis and sophisticated structural approaches to specifically design new vaccines to succeed where previous efforts have failed. Secondly, isolated antibodies themselves represent powerful drugs when developed and delivered as biopharmaceuticals. The ever-expanding list of approved antibody treatments and the large number of antibody products in development across a wide range of therapeutic areas indicate continued opportunities to treat and prevent human disease.
The use of antibody-based therapeutics in cancer is rapidly expanding, providing opportunities for specific targeting of the broad range of malignancies in different disease stages and ways to (re)-engage patients’ immune systems. Antibodies play an invaluable role in the treatment of inflammatory diseases, cardiovascular disease, bone disease and ophthalmic disease. For infectious diseases, particularly emerging infectious diseases, investigators can rapidly identify therapeutic antibodies for lifesaving treatment or prophylaxis. Such antibodies could be available far in advance of novel vaccines, and have already been used in clinical trials.
This symposium highlighted recent developments in antibody-based immunotherapy and vaccines, provide insights as to where the field in moving, and stimulate the interaction between experts in basic, applied and medical research and drug development.
Learn about the history, contributions, and initiatives of The Antibody Society;
Learn about antibodies approved for treatment and in clinical development by biotech and pharma;
Learn about major topics in antibody engineering and therapeutics, such as novel mechanisms of actions of therapeutic antibodies; novel antibody formats, such as antibody-drug conjugates and bispecific antibodies, aimed at improving specificity, efficacy and safety; analysis of antibody repertoires and B-cell lineages; and reverse engineering of vaccines
The Antibody Society: Our mission and current initiatives – Paul Carter, Ph.D. (VP, The Antibody Society) [Presentation also available in Members Only section]
Antibody therapeutics in clinical development: Antibodies to watch in 2018 – Janice Reichert, Ph.D. (Executive Director, The Antibody Society) [Presentation available in Members Only section]
Antibody-drug conjugates: license to kill – John Lambert, Ph.D. (ImmunoGen.)
Recharging the immune system with immunomodulatory antibodies – Alan Korman, Ph.D. (Bristol-Myers Squibb)
Novel antibody formats: More than twice the power – Paul Carter, Ph.D. (Genentech)
Insights provided by antibody repertoires and B cell analysis – Nina Luning Prak, M.D., Ph.D. (University of Pennsylvania)
iReceptor: A platform for exploring and analyzing antibody/B-cell and T-cell receptor repertoire data across diseases, labs, and institutions – Felix Breden, Ph.D. (Simon Fraser University) [Presentation available in Members Only section]
Presentations from the Symposium can be found on the Presentations page in the Members Only section of the Society’s website. Please login to access the PDFs, posted when speakers have provided permission.